Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced new data from its preclinical study of ZL-1503, the Company’s promising IL-13/IL-31R bispecific antibody, demonstrating its ability to ...

Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders ...

The BBC content job to replace Charlotte Moore is heating up with Zai Bennett dropping out and Tom McDonald and David ...

On Tuesday, Cantor Fitzgerald analysts maintained an Overweight rating on Zai Lab (NASDAQ:ZLAB) stock, with a price target of $56.00, well above the current trading price of $31.19. According to ...

1 Day ZLAB -1.45% DJIA -0.99% S&P Mid Cap 400 -1.55% Health Care/Life Sciences -1.07% ...

Median overall survival improved to 16.2 months with TTFields vs. 14.2 months for standard treatment. TTFields extended pain-free survival by 6.1 months, reaching a median of 15.2 months. Get ...

and no drug discontinuations - Company plans to initiate pivotal trial in 2L SCLC with selected optimal dose later this year - Zai Lab to host investor conference call and webcast to discuss data ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that updated data from an ongoing, global Phase 1a/1b clinical trial (NCT06179069) evaluating zocilurtatug pelitecan, or ZL-1310, ...

BAAR, Switzerland--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) ...

--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that updated data from an ongoing, global Phase 1a/1b clinical trial (NCT06179069) evaluating zocilurtatug pelitecan, or ...

Zai Lab Limited (NASDAQ:ZLAB) and NovoCure Limited (NASDAQ:NVCR) revealed landmark results from the Phase 3 PANOVA-3 trial at the 2025 ASCO Annual Meeting, marking the first therapy to show ...